Sarabjot Pabla

1.7k total citations · 1 hit paper
77 papers, 720 citations indexed

About

Sarabjot Pabla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sarabjot Pabla has authored 77 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 26 papers in Cancer Research. Recurrent topics in Sarabjot Pabla's work include Cancer Immunotherapy and Biomarkers (50 papers), Cancer Genomics and Diagnostics (19 papers) and Immunotherapy and Immune Responses (18 papers). Sarabjot Pabla is often cited by papers focused on Cancer Immunotherapy and Biomarkers (50 papers), Cancer Genomics and Diagnostics (19 papers) and Immunotherapy and Immune Responses (18 papers). Sarabjot Pabla collaborates with scholars based in United States, United Kingdom and Netherlands. Sarabjot Pabla's co-authors include Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Razelle Kurzrock, Shumei Kato, Yu Fujiwara, Sean T. Glenn, Carl Morrison, Felicia L. Lenzo and Blake Burgher and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Sarabjot Pabla

63 papers receiving 708 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy

2022 195 citations Shumei Kato, Mary Nesline et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarabjot Pabla United States	15	422	251	199	179	153	77	720
Paul DePietro United States	11	250 0.6×	186 0.7×	123 0.6×	90 0.5×	82 0.5×	41	451
Jun Ji China	12	160 0.4×	109 0.4×	370 1.9×	269 1.5×	133 0.9×	19	613
Sidharth Mahapatra United States	14	148 0.4×	98 0.4×	277 1.4×	98 0.5×	84 0.5×	32	513
Rachel Popow United States	5	261 0.6×	293 1.2×	97 0.5×	32 0.2×	133 0.9×	6	611
Tianli Cheng China	12	150 0.4×	89 0.4×	194 1.0×	138 0.8×	109 0.7×	25	493
Julia M. Jansen Germany	13	296 0.7×	415 1.7×	368 1.8×	173 1.0×	111 0.7×	21	902
Alicia Lenzen United States	7	133 0.3×	137 0.5×	183 0.9×	77 0.4×	75 0.5×	25	437
Dengxiong Li China	16	155 0.4×	83 0.3×	308 1.5×	189 1.1×	250 1.6×	68	639
Manuela Liguori Italy	8	317 0.8×	394 1.6×	283 1.4×	100 0.6×	74 0.5×	10	706
Emily Vucic United States	6	315 0.7×	254 1.0×	249 1.3×	104 0.6×	48 0.3×	9	616

Countries citing papers authored by Sarabjot Pabla

Since Specialization

Citations

This map shows the geographic impact of Sarabjot Pabla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarabjot Pabla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarabjot Pabla more than expected).

Fields of papers citing papers by Sarabjot Pabla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarabjot Pabla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarabjot Pabla. The network helps show where Sarabjot Pabla may publish in the future.

Co-authorship network of co-authors of Sarabjot Pabla

This figure shows the co-authorship network connecting the top 25 collaborators of Sarabjot Pabla. A scholar is included among the top collaborators of Sarabjot Pabla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarabjot Pabla. Sarabjot Pabla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nishizaki, Daisuke, Sharon H. Choi, Suzanna Lee, et al.. (2025). Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations. JCO Precision Oncology. 9(9). e2500304–e2500304. 1 indexed citations

Nishizaki, Daisuke, Hirotaka Miyashita, Suzanna Lee, et al.. (2025). B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades. ImmunoTargets and Therapy. Volume 14. 967–977.

Chen, Hui‐Zi, Na Hyun Kim, Daisuke Nishizaki, et al.. (2025). PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome. npj Genomic Medicine. 10(1). 21–21. 4 indexed citations

Seager, R. J., et al.. (2024). Immune checkpoint expression and co-expression landscape in gastroesophageal adenocarcinoma. SHILAP Revista de lepidopterología. 3. 100045–100045.

Nishizaki, Daisuke, Razelle Kurzrock, Hirotaka Miyashita, et al.. (2024). Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. ESMO Open. 9(4). 102942–102942. 18 indexed citations

Previs, Rebecca A., Maureen E. Cooper, Kyle C. Strickland, et al.. (2024). Comprehensive Genomic Testing: Tissue Stewardship and Best Practices. 10(2). 1 indexed citations

Nesline, Mary, Vivek Subbiah, Rebecca A. Previs, et al.. (2024). The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer. Oncology and Therapy. 12(2). 329–343. 3 indexed citations

Kurzrock, Razelle, Daisuke Nishizaki, Hirotaka Miyashita, et al.. (2023). Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer Medicine. 13(1). e6844–e6844. 9 indexed citations

Choi, Sharon, Razelle Kurzrock, Thomas J. O’Keefe, et al.. (2023). BTLA transcriptomic expression correlates with high levels of PD-1, PD-L2, and CTLA-4 checkpoints and with its ligand, HVEM, across diverse solid cancers.. Journal of Clinical Oncology. 41(16_suppl). e14641–e14641.

10.

Nesline, Mary, Rebecca A. Previs, Grace K. Dy, et al.. (2023). PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes. Cancers. 15(19). 4789–4789. 4 indexed citations

11.

Adashek, Jacob J., Shumei Kato, Daisuke Nishizaki, et al.. (2023). LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. Cancer Medicine. 12(12). 13155–13166. 24 indexed citations

12.

Seager, R. J., Shuang Gao, Mary Nesline, et al.. (2023). Sex-Specific Effects of Body Composition on Tumor Microenvironment in Non–Small Cell Lung Cancer. Annals of Thoracic Surgery Short Reports. 1(3). 465–468.

13.

Nesline, Mary, Paul DePietro, Maureen Cooper, et al.. (2023). The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.. Journal of Clinical Oncology. 41(16_suppl). 6506–6506. 1 indexed citations

14.

Severson, Eric A., Bhagelu R. Achyut, Mary Nesline, et al.. (2023). RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers. Journal of Molecular Diagnostics. 25(7). 454–466. 8 indexed citations

15.

Mukherjee, Sarbajit, R. J. Seager, Yong Hee Lee, et al.. (2021). Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma. Journal of Personalized Medicine. 11(12). 1324–1324. 1 indexed citations

16.

Patnaik, Santosh K., et al.. (2021). Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clinical and Research Reports. 2(12). 100254–100254. 6 indexed citations

17.

Gartrell, Robyn D., Douglas K. Marks, Emanuelle M. Rizk, et al.. (2019). Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma. Clinical Cancer Research. 25(8). 2494–2502. 17 indexed citations

18.

Papanicolau‐Sengos, Antonios, Ting‐Tai Yen, Devin Dressman, et al.. (2019). RNA-sequencing reveals immunotherapy targets in gynecological cancer.. Journal of Clinical Oncology. 37(8_suppl). 8–8.

19.

Gandhi, Shipra, Sarabjot Pabla, Mary Nesline, et al.. (2017). Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders.. Journal of Clinical Oncology. 35(15_suppl). 11565–11565. 3 indexed citations

20.

Pabla, Simarjot & Sarabjot Pabla. (2008). Real-time polymerase chain reaction. Resonance. 13(4). 369–377. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact